breast cancer

Galen Perdikis, MD, left, and G. Patrick Maxwell, MD.

Dedication to advancing breast reconstruction surgery for patients links Perdikis, Maxwell

Perdikis now holds the recently established G. Patrick Maxwell, M.D. Chair of the Department of Plastic Surgery at Vanderbilt University Medical Center.

Abigail Lindsey Rich talks about her research poster with Vanderbilt-Ingram Cancer Center director Ben Ho Park, MD, PhD. (photo by Donn Jones)

Speakers share history of hereditary cancers at scientific retreat 

Speakers at the Vanderbilt-Ingram Cancer Center 25th Annual Scientific Retreat detailed the history of hereditary cancer discoveries and gave overviews about ongoing research. 


Breast cancer risk variants identified for women of African ancestry

A study led by researchers from Vanderbilt-Ingram Cancer Center sheds light on some of the genetic variants that make breast cancer more deadly for women of African ancestry and significantly reduces the disparity in knowledge for assessing their genomic risk factors.

Scalp cooling allows woman to keep hair during chemotherapy

The Food and Drug Administration first granted marketing approval for the DigniCap system for patients with breast cancer in 2015, then in 2017 the FDA expanded the authorization, making it the first cooling cap cleared for use in cancer patients with solid tumors, such as breast cancer, ovarian cancer and colorectal cancer.

Authors on the study included, from left, Jennifer Pietenpol, PhD, Melinda Sanders, MD, Brian Lehmann, PhD, Vandana Abramson, MD, and Yu Shyr, PhD. (photo by Donn Jones)

Clinical trial shows efficacy for atezolizumab combined with carboplatin

The study team included, from left, Paula Gonzalez-Ericsson, MD, Xiaopeng Sun, Justin Balko, PharmD, PhD, and Brandie Taylor, MS. (photo by Donn Jones)

Vulnerability found in immunotherapy-resistant triple-negative breast cancer

Vanderbilt researchers have discovered a druggable target on natural killer cells that could potentially trigger a therapeutic response in patients with immunotherapy-resistant, triple-negative breast cancer.

1 2 3 12